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Abstract: Patchoulol is a sesquiterpene alcohol and an important natural product for the perfume
industry. Corynebacterium glutamicum is the prominent host for the fermentative production of amino
acids with an average annual production volume of ~6 million tons. Due to its robustness and
well established large-scale fermentation, C. glutamicum has been engineered for the production of a
number of value-added compounds including terpenoids. Both C40 and C50 carotenoids, including
the industrially relevant astaxanthin, and short-chain terpenes such as the sesquiterpene valencene
can be produced with this organism. In this study, systematic metabolic engineering enabled
construction of a patchoulol producing C. glutamicum strain by applying the following strategies:
(i) construction of a farnesyl pyrophosphate-producing platform strain by combining genomic
deletions with heterologous expression of ispA from Escherichia coli; (ii) prevention of carotenoid-like
byproduct formation; (iii) overproduction of limiting enzymes from the 2-C-methyl-D-erythritol
4-phosphate (MEP)-pathway to increase precursor supply; and (iv) heterologous expression of the
plant patchoulol synthase gene PcPS from Pogostemon cablin. Additionally, a proof of principle
liter-scale fermentation with a two-phase organic overlay-culture medium system for terpenoid
capture was performed. To the best of our knowledge, the patchoulol titers demonstrated here are the
highest reported to date with up to 60 mg L−1 and volumetric productivities of up to 18 mg L−1 d−1.
Keywords: patchoulol; Corynebacterium glutamicum; sesquiterpene; metabolic engineering; algae;
Escherichia coli
1. Introduction
Terpenoids are a diverse group of natural compounds that can be found in all organisms with
numerous roles including, but not limited to, signaling, communication, defense, electron transfer,
membrane fluidity, and pigmentation [1]. Terpenoids, also known as isoprenoids, are composed of
five carbon (C5) units of isopentenyl pyrophosphate (IPP) and its isomer dimethylallyl pyrophosphate
(DMAPP). IPP and DMAPP are produced by either the 2-C-methyl-D-erythritol 4-phosphate (MEP) or
the mevalonate (MVA) pathways. Both pathways are capable of producing the same IPP and DMAPP
precursors and the MEP pathway is found in most bacteria as well as plant plastids, while the MVA
pathway is found commonly in eukaryotes and archaea [1,2]. These building blocks are condensed by
Genes 2018, 9, 219; doi:10.3390/genes9040219 www.mdpi.com/journal/genes
Genes 2018, 9, 219 2 of 15
prenyltransferases to form larger carbon backbones (C10–Cn) that can be formed into the vast array of
terpenoid molecules via the modular enzymatic reactions of the terpene synthases. Terpene backbones
can also be functionalized by further down-stream enzymes such as cytochrome P450s, yielding the
observed array of chemical diversity of terpenoid natural compounds [3].
The demand for naturally produced terpenoids is increasing due to increased consumer awareness
and growing demand for naturally sourced materials in everyday products such as food, cosmetics,
perfumes, and household chemicals. Although some terpenoids can be extracted from plant
material, terpenoid production processes using bio-based microbial platforms are gaining attention as
sustainable and economical alternatives. Terpenoid biosynthesis is inherently modular, with defined
enzymatic steps leading from precursors to specific terpenoid products [3]. As all organisms contain
the building blocks for terpenoid biosynthesis, it is possible to selectively transfer terpene synthases
from organisms that naturally produce a desired compound into biotechnologically amenable
hosts. Controlled microbial fermentation and production of terpenoids can have numerous benefits
over harvesting and extraction from native organisms including containment, scalability, reliable
product yield, shorter generation times, and minimizing environmental impacts from harvesting or
agricultural cultivation.
Farnesyl pyrophosphate (FPP), the prenylated precursor of sesquiterpenoids (C15), is formed
by condensation of DMAPP and two molecules of IPP by the enzyme farnesyl pyrophosphate
synthase (FPPs). Sesquiterpenoid products are generated from FPP by sesquiterpene synthases.
The sesquiterpenoid alcohol patchoulol is harvested from the leaves of the plant Pogostemon cablin,
and is used as a component in perfumes, incense, and natural insect repellents [4]. P. cablin is
traditionally cultivated in Indonesia and India where steam distillation of leaves is used to extract
its essential oil, the main odor compound in this oil is the sesquiterpenoid alcohol patchoulol [5,6].
Patchouli oil is currently produced via traditional agriculture and steam distillation, 2.2–2.8 kg of
patchouli oil can be extracted from 100 kg of dried patchouli leaves. This process lasts 8 hours and
can consume 40 liters of kerosene [6]. As this process is energy and resource intensive, microbial
fermentative processes for the production of patchoulol could minimize its environmental footprint
and improve product yields. The conversion of FPP to patchoulol is mediated by a single enzyme,
the patchoulol synthase (PcPS; PTS, uniprot: Q49SP3) [5,7], and heterologous expression of this enzyme
has been used to produce this fragrance compound in several microbial hosts including Saccharomyces
cerevisiae [8], the moss Physcomitrella patens [9] and the green microalga Chlamydomonas reinhardtii [10].
Mixtures of sesquiterpenes and alcohols present in patchouli oil obtained by fermentation have been
marketed (e.g., by Firmenich). It was shown that overproduction of the patchoulol synthase in
Escherichia coli produced several sequiterpenes besides patchoulol [5]. Thus, this product promiscuity
could find suitable applications in protein engineering towards other sequiterpenes and the specificity
for production of patchoulol itself could be a target for further enzyme engineering studies for the PcPS.
The Gram-positive bacterium Corynebacterium glutamicum is the workhorse of industrial
biotechnology for amino acid production and is already cultivated in industrial processes for the
production of L-glutamate and L-lysine. Fermentations with this host are characterized by robust
growth, high cell densities and high volumetric productivities [11–13]. The annual production
volume of L-glutamate and L-lysine in industrial processes with C. glutamicum is estimated to reach
6 million tons in 2023 [14]. Currently, industrial production plants for C. glutamicum cultivation
are found worldwide indicating that engineering of this organism for expanded profiles of natural
products has great biotechnological and commercial value potentials. C. glutamicum is not only a
natural L-glutamate producer, but also accumulates a yellow carotenoid, decaprenoxanthin, in its
membranes [15,16]. The carotenoid biosynthesis of C. glutamicum has been analyzed in more detail
over the last years [15]. Based on this knowledge, C. glutamicum has been engineered for production of
a range of high value terpenoids including short-chain terpenoids [17,18] and various C40 and C50
carotenoids [19,20]. Besides gene deletion, integration and overexpression, also other methodologies
such as regulator engineering [21], general transcription machinery engineering [22] and on-demand
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gene expression with photocaged-IPTG [18] were successfully demonstrated in this host to develop
terpenoid overproducing strains. Furthermore, coproduction of the terpenoid astaxanthin and the
amino acid L-lysine by a single C. glutamicum strain was established [23]. The coproduction of
two value-added compounds represents a novel fermentation strategy in which a biomass-bound and
a secreted substance were simultaneously produced during a single fermentation run. This example
indicates the great volumetric productivity potential of engineered C. glutamicum for feed market
applications [23].
In this work, we seek to expand the product profile range of C. glutamicum by engineering
this organism for the production of the sesquiterpenoid perfume product patchoulol. Here,
patchoulol production was achieved by combining construction of an FPP-producing platform strain,
wherein carotenoid-like byproduct formation was prevented, with overproduction of rate-limiting MEP
pathway enzymes. This strain was used for heterologous expression of the P. cablin patchoulol synthase
(PcPS) and patchoulol production as well as a proof-of-principle liter-scale bioreactor fermentation
with product capture using a two-phase organic solvent-culture overlay were demonstrated.
2. Materials and Methods
2.1. Bacterial Strains, Media and Growth Conditions
The strains and plasmids used in this work are listed in Table 1. C. glutamicum ATCC 13032 [24] was
used as the parental strain for all metabolic engineering approaches. Pre-cultivation of C. glutamicum
strains was performed in BHI/LB medium (Carl Roth, Karlsruhe, Germany) with 50 mM glucose.
For main cultivation in CGXII minimal medium [25], these pre-cultivated cells were washed once with
CGXII medium without carbon source and inoculated to an initial OD600 of 1. 100 mM glucose was
added as carbon and energy source. Standard cultivations of C. glutamicum were performed at 30 ◦C in
a volume of 20 mL in 100 mL flasks without baffles shaking at 120 rpm. The OD600 was measured in
dilutions using a Shimadzu UV-1202 spectrophotometer (Duisburg, Germany). For capturing of the
volatile patchoulol 10% (v/v) of dodecane was added to the main culture [17]. E. coli DH5α was used
as host for all cloning aspects and cultivated in LB medium at 37 ◦C overnight. When appropriate,
tetracyclin, spectinomycin or kanamycin were added in concentrations of 5, 100 and 25 µg mL−1,
respectively. Gene expression was induced by addition of 1 mM IPTG to the main culture.
Table 1. Strains and plasmids used in this study.
STRAIN; PLASMID Relevant Characteristics Reference
Corynebacterium glutamicum STRAINS
WT Wild type, ATCC 13032 [24]
∆crtE∆idsA crtE (cg0723) and idsA (cg2384) deletion mutant of ATCC 13032 [17]
∆crtOP∆idsA∆crtB2I’I2 crtOP (cg0717- cg0723), idsA (cg2384) and crtB2I’I2 (cg2668-cg2672) deletionmutant of ATCC 13032 this work
PAT1 ∆crtE∆idsA (pECXT-ispA-PcPS)(pEKEx3) this work
PAT2 ∆crtOP∆idsA∆crtB2I’I2 (pECXT_ispA-PcPS)(pVWEx1) this work
PAT3 ∆crtOP∆idsA∆crtB2I’I2 (pECXT_ispA-PcPS)(pVWEx1_dxs-idi) this work
OTHER STRAINS
Escherichia coli DH5α F-thi-1 endA1 hsdr17(r-, m-) supE44 ∆lacU169 (Φ80lacZ∆M15) recA1 gyrA96 [26]
PLASMIDS
pOpt_PcPS Shuttle vector containing PcPS from Pogostemon cablin codon-optimized forCorynebacterium glutamicum (gene synthesis) (Uniprot Q49SP3) this work
pEC-XT99A (pEC-XT) TetR, PtrclacIq, pGA1 oriVCg, C. glutamicum/E. coli expression shuttle vector [27]
pEC-XT_ispA-PcPS
pEC-XT derivative for IPTG-inducible expression of ispA from E. coli and
codon-optimized PcPS from P. cablin (Uniprot Q49SP3) containing an
artificial ribosome binding site
this work
pEKEx3 SpecR, PtaclacIq, pBL1 oriVCg, C. glutamicum/E. coli expression shuttle vector [28]
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Table 1. Cont.
STRAIN; PLASMID Relevant Characteristics Reference
PLASMIDS
pEKEx3_araBAD pEKEx3 derivative for IPTG-inducible expression of the araBAD operonfrom E. coli containing an artificial ribosome binding site this work
pEKEx3_xylAB
pEKEx3 derivative for IPTG-inducible expression of xylA from Xanthomonas
campestris and xylB from C. glutamicum containing an artificial ribosome
binding site
[29]
pVWEx1 Km
R, PtaclacIq, pHM519 oriVCg, C. glutamicum/E. coli expression
shuttle vector
[30]
pVWEx1_dxs-idi pVWEx1 derivative for IPTG-inducible expression of dxs (cg2083) and idi(cg2531) from C. glutamicum containing an artificial ribosome binding site [18]
pK19mobsacB Km
R; E. coli/C. glutamicum shuttle vector for construction of insertion and
deletion mutants in C. glutamicum (pK18 oriVEc sacB lacZα)
[31]
pK19mobsacB∆crtE pK19mobsacB with a crtE (cg0723) deletion construct [17]
pK19mobsacB∆idsA pK19mobsacB with a idsA (cg2384) deletion construct [17]
pK19mobsacB∆crtOP pK19mobsacB with a crtOP (cg0717-cg0723) deletion construct this work
pK19mobsacB∆crtB2I’I2 pK19mobsacB with a crtB2I’I2 (cg2668-cg2672) deletion construct this work
2.2. Recombinant DNA Work
Plasmids were constructed with Gibson assembly [32] or classical restriction and ligation.
PCR-generated fragments (All-in HiFi, highQu, Kraichtal, Germany) were assembled into isolated
plasmids (Plasmid GeneJET Miniprep kit, Thermo Fisher Scientific, Schwerte, Germany) that
were linearized by restriction. Oligonucleotides used in this study were obtained from Metabion
(Planegg/Steinkirchen, Germany) and are listed in Table 2. Standard reactions like restriction, and PCR
were performed as described previously [33]. If applicable, PCR products were purified using the
PCR clean-up and gel extraction kit (Macherey-Nagel, Düren, Germany). For transformation of E. coli
DH5α, the RbCl method was used and C. glutamicum was transformed via electroporation [34] at
2.5 kV, 200 Ω, and 25 µF. Vector construction was confirmed by sequencing of cloned inserts.
Table 2. Oligonucleotides used in this study.
Strain DNA Sequence
crtOP-A AAAACCCGGGTAGCTCCATATAACGTGCCG
crtOP-B CCCATCCACTAAACTTAAACAGATTGTCATGCCATTGTCCAT
crtOP-C TGTTTAAGTTTAGTGGATGGGACGATACTGCTAATAGCAATTCATCAGATATAA
crtOP-D AAAACCCGGGATGTGTGGGAGGCTTCGC
crtOP-E GTGACCATGAGGGCGAAAGC
crtOP-F AAAACAATGCGCAGCGCA
crtB2I’I2-A AAAACCCGGGGTCAGTGCTGTCATCGGTAC
crtB2I’I2-B CCCATCCACTAAACTTAAACAATCTTGCTGATCAGCCAC
crtB2I’I2-C TGTTTAAGTTTAGTGGATGGGAACAGTGTGGATCGGACTTAA
crtB2I’I2-D AAAACCCGGGCTGCATGAATGTTGGTGAAC
crtB2I’I2-E CGGACTTGATGCTGCAGC
crtB2I’I2-F TGAGCCGCAACCAATTGAAG
PcPS-fw AACTGCCACACGAACGAAAGGAGGCCCTTCAGATGGAGCTGTACGCCCAGAG
PcPS-rv GCATGCCTGCAGGTCGACTCTAGAGGATCTTAGCCGCTGCCGTAGGG
ispA-fw ATGGAATTCGAGCTCGGTACCCGGGGAAAGGAGGCCCTTCAGATGGACTTTCCGCAGCAACTCG
ispA-rv GTTCGTGTGGCAGTTTTATTTATTACGCTGGATGATGTAGTCC
araBAD-fw TGCAGGTCGACTCTAGAGGAAAGGAGGCCCTTCAGATGGCGATTGCAATTGGCCT
araBAD-rv GAGCTCGGTACCCGGGGATCTTACTGCCCGTAATATGCCT
pEC-XT fw AATACGCAAACCGCCTCTCC
pEC-XT rv TACTGCCGCCAGGCAAATTC
Sequence in bold: artificial ribosome binding site; sequence in italics: linker sequence for hybridization.
2.3. Deletion and Exchange Mutagenesis in the Genome of Corynebacterium glutamicum
For targeted deletion of the carotenogenic operons (cg0717-cg0723 and cg2668-cg2672),
crtE (cg0723) and idsA (cg2384), the suicide vector pK19mobsacB was used [31]. Genomic regions
flanking the corresponding genes/operons were amplified from genomic DNA of C. glutamicum WT
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using primer pairs A/B and C/D (Table 2), respectively. The resulting amplificates were cloned into
pK19mobsacB via Gibson method resulting in the construction of deletion vectors (Table 1). Deletions
were carried out via two-step homologous recombination as well as the selection for the first and
second recombination events were carried out as described previously [25]. Successful removals of
genes or operons were verified by PCR analysis of the constructed mutants using primer pair E/F
(Table 2).
2.4. Fermentation of Corynebacterium
A bioreactor with a total volume of 3.7 L and a working volume of 2.0 L was used for batch and
fed-batch fermentations (KLF, Bioengineering AG, Switzerland). The stirrer axis was equipped with
three six-bladed rushton turbines in a distance of 6 cm, 12 cm, and 18 cm from the bottom. The relative
dissolved oxygen saturation in the medium (rDOS) (Mettler-Toledo, Greifensee, Switzerland) and
pH (Hamilton, Switzerland) were monitored with electrodes. The pH was kept at 7.0 by automated
addition of KOH 4 M and 10% (w/w) phosphoric acid. The initial volume of the fermentations was
2 L. For feeding approximately 730 mL volume was added, depending on the rDOS. Fermentations
were performed with 0.2 bar overpressure and an aeration rate of 2 NL min−1. The initial stirrer
frequency was set to 200 min−1 and speed was increased in steps of 2% when rDOS profile felt below
30% (fed-batch) or 60% (batch), respectively.
Struktol® was added manually as an antifoam reagent. For the fed-batch procedure the feeding
profile was activated when the rDOS was about 60% and stopped when rDOS felt below 60%.
Samples were taken regularly and were stored at 4 ◦C until further use. Plasmid-driven gene expression
was induced in the exponential growth phase (t = 5 h). Capturing of patchoulol was conducted through
a dodecane overlay that was applied 5 (batch) or 25 (fed-batch) hours after inoculation.
The fermenters were inoculated with a fresh overnight culture grown at 30 ◦C and 120 rpm
(amplitude: 2.5 cm) to an initial OD of ~1. The preculture medium contained: 13.6 g L−1 soypeptone,
7 g L−1 yeast extract, 2.5 g L−1 NaCl, 2.3 g L−1 K2HPO4, 1.5 g L−1 KH2PO4, 0.14 g L−1 MgSO4·H2O,
40 g L−1 D-glucose monohydrate, 25 mg L−1 tetracycline, and 25 mg L−1 kanamycin. The fermentation
was performed on the basis of the same medium. Feeding medium contained 300 g L−1 D-glucose
monohydrate and 75 g L−1 yeast extract.
2.5. Patchoulol Capture and Quantification
The clean dodecane supernatants were analyzed via GC–MS using a TraceGC gas chromatograph
(Thermo Scientific, Waltham, MA, USA) and ITQ ion trap mass spectrometer (Thermo Scientific,
Waltham, Massachusetts, USA equipped with a AS 3000 autosampler (Thermo Scientific, Schwerte,
Germany). As a column system a 30 m× 0.25 mm VF-5 ms column coated with 0.25 µm of 5% diphenyl
and 95% dimethylsiloxane (Varian GmbH, Darmstadt, Germany) was used. Temperature profile was
set as the following: injector (250 ◦C), interface (250 ◦C) and ion source (220 ◦C). 1 µL of sample was
injected in splitless mode. A constant flow of 1 mL min−1 helium was used as a carrier gas. The oven
temperature profile was set as the following: 80 ◦C for one minute, then raised to 120 ◦C at 10 ◦C
min−1, followed by 3 ◦C min−1 to 160 ◦C, and further to 270 ◦C at 10 ◦C min−1, which was held for
2 min. Mass spectra were recorded after the dodecane peak eluted (12 min) using a scanning range
of 50–750 m/z at 20 scans s−1. Chromatograms were evaluated with Xcalibur software version 2.0.7
(Thermo Scientific, Germany). The NIST 05 library (National Institute of Standards and Technology,
Gaithersburg, MD; ThermoFinnigan) was used to identify substances for which no standard was
available. Standard calibration curves in the range of 1–450 µM (or 0.5–100 mg L−1) patchoulol in
dodecane were used to quantify the amount of patchoulol (R2 ≈ 0.99). 250 µM α-humulene was
applied in each sample as internal standard. Extracted-ion chromatograms (XIC) with mass ranges of
93.00 (α-humulene), 138.50 and 222.00 (patchoulol) were used (see Figure S2).
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3. Results
3.1. Patchoulol Production in Shake Flasks with Metabolically Engineered Corynebacterium glutamicum
C. glutamicum possesses two genes encoding GGPP synthases (Figure 1) with idsA encoding
the major GGPPS. Their biochemical characteristics and mutant studies revealed that primarily
GGPP is formed by idsA and crtE [35]. Therefore, the deletion mutant ∆crtE∆idsA derived from
C. glutamicum wild type ATCC 13032 that was already employed for successful production of
short-chain terpenoids [17,18] was used here as the base strain for patchoulol production (Table 3).Genes 2018, 9, x FOR PEER REVIEW  6 of 15 
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Figure 1. Patchoulol production by engineered Corynebacterium glutamicum. (a) Schematic representation
of the patchoulol pathway in recombinant C. glutamicum. Ov re pressed genes are in bold, endogenous
genes are in circles, heterologous genes are boxed (clear background for bacterial origin and shaded
background for eukaryotic origin), genes deletions are indicated by red crosses, gene names are
indicated next to the reactions they catalyze, single reaction are represented by arrows, pathways
with more than one reaction by dashed arrows. Abbreviations: dxs, 1-deoxy-D-xylulose-5-phosphate
synthase; ispH, 4-hydroxy-3-methylbut-2-en-1-yl diphosphate r ductase; idi, isopentenyl-diphosphate
isomerase; idsA, geranylgeranyl diphosphate synthase; crtE, geranylgeranyl diphosphate synthase; crtB,
phytoene synthase; crtI, phytoene desaturase; crtEb, lycopene elongase; crtYe/f, lycopene β-cyclase; xylB,
xylulokinase; ispAEc, farnes pyro hosphate synthase from Escherichia coli; PcPS, plant patchoulol
synthase from Pogostemon cablin; xylAXc, xylose isomerase from Xanthomonas campestris; araAEC, arabinose
isomerase from E. coli; araBEC, ribulokinase from E. coli; araDEC, ribulose-5-phosphate-4-epimerase
from E. coli; GAP, gl cerol aldehyde ph sphate; DXP, 1-deoxy-D-xylulose-5-phosphate; HMBPP,
4-hydroxy-3-methylbut-2-enyl diphosphate; IPP, isopentenyl pyrophosphate; DMAPP, dimethylallyl
pyrophosphate; FPP, farnesyl pyro sphate; GGPP, geranylgeranyl pyrophosphate; (b) Carotenogenic
genes and operons in C. glutamicum. The major crt operon contains: crtE (cg0723), geranylgeranyl
diphosphate synthase; (cg0722); crtB (cg0721), phytoene synthase; crtI (cg0720), phytoene desaturase;
crtYe (cg0719); crtYf (cg0718); crtEb (cg0717), phytoene synthase. The small crt operon contains:
crtB2 (cg2672), phytoene synthase; crtI2′ (cg2670), non-functional phytoene desaturase; crtI2” (cg2668),
non-functional phytoene desaturase. idsA (cg2384), geranylgeranyl diphosphate synthase.
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The deletion of both GGPP synthases genes idsA and crtE results in the accumulation of the central
terpenoid precursor molecules IPP and DMAPP due to the lack of other short-chain prenyltransferases
in C. glutamicum. Heterologous overexpression of ispA from E. coli coding for FPP synthase and
overexpression of a codon-optimized PcPS encoding the patchoulol synthase from P. cablin (Uniprot
Q49SP3) in this strain enabled patchoulol production from glucose (PAT1) (Figure 1). PAT1 cells even
exhibited a distinct earthy odor of the patchouli alcohol under IPTG induction on the agar plate.
Cultivation of PAT1 in 20 mL CGXII with 100 mM glucose produced 0.20 ± 0.03 mg L−1 patchoulol
(concentrations are given based on the total culture medium volume) within 48 h incubation. 1 mM
IPTG was added to the culture medium in the exponential growth phase (t = 5 h) in order to induce
plasmid-driven gene expression of the prenyltransferase and terpene synthase genes. At the same time,
2 mL of dodecane was added as an overlay to capture the volatile product. Interestingly, C. glutamicum
PAT1 cells exhibited a colored phenotype. The pigmentation may be due to the formation of (a) C30
carotenoid-like structure(s) under the assumption that endogenous carotenogenic enzymes accept FPP
as substrate in the absence of GGPP (Figure 1). Thus, deletion of all carotenogenic genes from the
C. glutamicum genome was conducted in order to prevent formation of undesired terpenoid byproducts
(see Figure S1). As expected, the corresponding strain PAT2 lacking both crt operons [15] as well as
the major GGPP synthase [35] showed the desired white phenotype indicating that carotenoid-like
byproducts were no longer accumulated (Figure 1 and Figure S1). The patchoulol titer of PAT2
(0.22 ± 0.02 mg L−1) remained comparable to that produced by PAT1 (Table 3).
As known from production of other short- and long-chain terpenoids by recombinant
C. glutamicum [18,36], precursor supply was expected to limit patchoulol production and therefore was
set as a target for further engineering. Overproduction of the first enzyme of the MEP-pathway, Dxs,
as well as the isomerase Idi, have been shown to be highly effective for improved terpenoid production
both in C. glutamicum [17,36] and E. coli [37,38] due to the generation of increased precursor supply
for terpenoid products. Here, plasmid-driven overexpression of endogenous dxs and idiimproved
patchoulol production approximately 2-fold (Table 3). The strain PAT3 produced 0.46 ± 0.07 mg L−1
patchoulol in shake flask cultures within 48 h. The volumetric productivity of 0.23 ± 0.03 mg L−1 d−1
is among the highest reported for patchoulol production [10].
Table 3. Patchoulol production from 100 mM glucose in shake flasks (20 mL) after 48 h. Patchoulol
titers and productivity refer to the total culture volume and are represented as mean values and
standard deviations of biological triplicates. For comparison wild-type C. glutamicum grew to a biomass
concentration of 5.4 g L−1 CDW from 100 mM glucose in the presence of dodecane [17].
PAT1 PAT2 PAT3
CDW [g L−1] 4.4 ± 0.6 4.2 ± 0.6 4.2 ± 0.7
Titer [mg L−1] 0.20 ± 0.03 0.21 ± 0.02 0.46 ± 0.07
Vol. productivity [mg L−1 d−1] 0.10 ± 0.01 0.11 ± 0.01 0.23 ± 0.03
3.2. Patchoulol Production from Alternative Carbon Sources
In order to test if patchoulol production from C. glutamicum could be conducted in a sustainable
manner on carbon sources which do not compete for resources with food and feed production,
small scale fermentations of PAT3 were carried out with the pentoses L-arabinose and D-xylose.
These pentoses can be derived from agricultural waste products such as wheat or rice straw
hydrolysates [29,39]. Since the PAT3 strain is not able to grow on either substrate, metabolic engineering
for utilization of arabinose and xylose was performed. First, plasmid-driven overproduction of
arabinose isomerase, ribulokinase and ribulose-5-phosphate-4-epimerase encoded by the araBAD
operon from E. coli enabled C. glutamicum growth and the production of patchoulol. These enzymes
convert arabinose to xylulose 5-phosphate, a central intermediate of the pentose phosphate pathway.
Second, plasmid-driven overproduction of xylose isomerase and xylulokinase encoded by xylA from
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X. campestris and xylB from C. glutamicum, respectively, allowed phosphorylation and isomerization of
the pentose sugar to xylulose 5-phosphate [29].
As shown in Figure 2 patchoulol production was possible from the cultivation of engineered
C. glutamicum on the pentoses arabinose and xylose. The control strain PAT3 (pEKEx3) produced
0.41 ± 0.08 mg L−1 patchoulol from 10 g L−1 glucose. The strains PAT3 (pEKEx3_araBAD) and PAT3
(pEKEx3_xylAB) produced 0.15 ± 0.04 mg L−1 and 0.23 ±mg L−1 patchoulol on the basis of 10 g L−1
of the respective pentose sugar. The observed differences in patchoulol titers may reflect that glucose
can be catabolized in glycolysis and/or the oxidative pentose phosphate pathway while arabinose
and xylose catabolism proceeds via the oxidative pentose pathway. To comprehend the differences
of growth and production between the substrates glucose, arabinose, and xylose a full carbon-13
based labelling flux metabolic analysis is needed, however, the data depicted in Figure 2 provide a
proof-of-concept that patchoulol production from xylose and arabinose is possible.
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4. Discussion
In this work, patchoulol production by C. glutamicum, the microbial cell factory for the
million-ton-scale production of amino acids [14], was demonstrated (see Figure S2). Strain engineering
addressed heterologous overproduction of FPP synthase, overproduction of codon-optimized
plant patchoulol synthase (PcPS), prevention of terpenoid byproducts, increased flux through the
MEP-pathway and balancing of the DMAPP to IPP ratio. To the best of our knowledge, the titer of
60 mg L−1 and the volumetric productivity of 18 mg L−1 d−1 achieved in 2 L bioreactor cultures are
the highest patchoulol yields reported to date for microbial fermentation. For comparison, the highest
reported titers and volumetric productivities obtained with phototrophic hosts were ~1 mg L−1 and
~0.23 mg L−1 d−1, respectively, [10].
First, heterologous overpro uction of FPP synthase and the plant patchoulol synthase were
combined in PAT1, which resulted i the formation of patchoulol. However, overproduction of FPP in
the presence of endogenous carotenogenic enzymes CrtB and CrtI, but in the absen e of their cognate
substrat GGPP, resulted in the accum lation of a carotenoid-like pigment indicating the native
enzymes have some affinity for the produced FPP. It is conceivabl that C30 ca tenoi s, for example,
4,4′- iapolycopene have bee formed. Thus, eletion of the caroten genic ope ons and ge es in
the wild-type background strain were performed to avoid accumulati n of untargeted terpenoid
by-products. Although deletion of the carotenogenic genes did not improve patchoulol prod ction,
the white cells of PAT2 and PAT3 may be favorable for patchoulol downstream proc ssing. Usually,
clear products are preferred for cosmetic ingredients and extraction of colored terpenoid pigment
by-products can thus be avoided in these strains.
Patchoulol production could be improved by 2-fold due to an improved flux through the
MEP-pathway, mediated by the overexpression of dxs, and an improved balance of the precursors
DMAPP and IPP was achieved by the overexpression of idi. The strain PAT3 produced ~0.5 mg L−1
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patchoulol in 20 mL scale from 100 mM glucose. The MEP-pathway is supposed to be heavily regulated
at many levels [1,40] and overexpression of both dxs and idi were shown to be beneficial for improving
terpenoid production from several organisms, including E. coli and C. glutamicum. Indeed, dxs and idi,
are considered the main rate-limiting steps within the MEP pathway [37,41]. While overproduction
of Dxs enhances the flow through the MEP pathway to ultimately produce more IPP and DMAPP,
the cause for the beneficial role of Idi overexpression, and its effect on IPP and DMAPP ratios, is still
under investigation. In E. coli, overproduction of Idi led to a shift of the natural IPP and DMAPP
ratio of 5:1 [42] towards DMAPP, thus allowing for the production of more FPP since it is made by
two molecules of IPP and one molecule of DMAPP [37].
Production titers of the sesquiterpene (+)-valencene in C. glutamicum were shown to be improved
by the use of caged-IPTG, allowing photo-induced production onset with UV light, compared to
conventional IPTG in microtiter-scale production experiments [18]. Whether this effect can be
transferred to patchoulol production in flask or even bioreactor scale experiments needs to be evaluated.
However, the relatively high price of caged-IPTG compared to IPTG, makes utilization in larger scales
not feasible [18].
After establishment of patchoulol production from C. glutamicum in small scale (20 mL), scale up
was conducted. Here, the 100-fold increase in scale from 20 mL to 2 L was successfully performed in a
bioreactor. A 30-fold increased patchoulol titer in comparison to shake flasks was observed. The strong
improvement is likely due to improved oxygen input and saturation in the bioreactor compared to
shake flasks and/or the consistency of pH in the controlled reactor. A beneficial effect due to improved
dodecane mixing with the microbial culture is also a likely factor in the observed product titers.
Dodecane captures volatile hydrophobic compounds and also supports the release or extraction of these
compounds from hydrophobic biological membranes [43]. In the fed-batch fermentation, a patchoulol
titer of ~60 mg L−1 was achieved within 142 h of cultivation, corresponding to a 130-fold increase in
productivity in comparison to the small-scale flask fermentation and an about 4-fold increase compared
to the batch-mode bioreactor culture. The significant drop in the relative dissolved oxygen (rDOS) at
25 h can be explained with coalescence due to dodecane application. With a volumetric productivity
of ~18 mg L−1 d−1 the production process presented here is superior to other production systems
in respect to maximal titers and volumetric productivities. Both batch and fed-batch fermentations
conducted here had maximal volumetric productivities around 53 h after inoculation, with 6.4 and
18 mg L−1 d−1, respectively. In this work, patchoulol was captured in a dodecane phase, allowing a
first separation of the product from the cell fraction. Dodecane as a linear petrochemical hydrocarbon
is considered a green solvent from the cluster 2 of the chemometric solvent selection guide with a high
confidence level [44]. Alternatively, patchoulol capture is possible with isopropyl myristate, which is
classified as a green solvent [45]. Both in batch and fed-batch fermentations, plasmid expression was
induced 5 h after inoculation. Since the strain PAT3 overproduces the terpenoid precursor molecules
DMAPP and IPP, accumulation of these toxic compounds might affect the cells negatively as has been
shown for Bacillus subtilis and E. coli [46].
Interestingly, PAT3 cells cultivated under fed-batch mode produced additional sequiterpenes.
According to the GC-MS library search, azulene and caryophyllene. However, the peak intensities
of these products were much lower and product formation occurred only in the late stationary
phase (data not shown). The promiscuity of the used patchoulol synthase from P. cablin was already
mentioned in literature with a least 13 additional sequiterpene products [5]. A rough comparison of
the in vitro enzymatic activity of ~0.02 unit mg−1, corresponding to 213,000 µg g CDW−1 d−1 [7,47] of
purified PcPS is in accordance with the volumetric productivity ~15 mg L−1 d−1, 1000 µg g CDW−1
d−1, of this study under the assumption that approximately 0.3% of the cellular protein of the producer
strain is PcPS.
Sequiterpenes are interesting products and their heterologous production has been in established
in several microorganisms. The biofuel component farnesene [48] can be produced with volumetric
productivities of up to 16.9 g L−1 d−1 and a maximum titer of 104.3 g L−1 [49], which is one of the
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highest reported terpenoid titers so far. Heterologous production of the anti-malaria drug precursor
artemisinic acid is a prominent example for a high pricing terpenoid that was established in both
eukaryotic and prokaryotic host organisms, S. cerevisiae and E. coli, respectively. A titer of 27.4 g L−1
amorphadiene is one of the highest reported for E. coli whereas functionalization of this sesquiterpene
by a plant-based P450 enzyme enabled production of 105 mg L−1 artemisinic acid [50]. To the best
of our knowledge, artemisinic acid production reached 25 g L−1 with yeast, which is the highest
reported to date [51]. These overproducing strains share intensive metabolic engineering, especially
the expression of the de-regulated MEV-pathway, which in bacterial hosts has been demonstrated to
be a powerful strategy for boosting overall terpenoid yields and could also be a suitable target for
C. glutamicum. Establishment of this second precursor pathway might result in a significant increase
of DMAPP and IPP production as the heterologous MEV-pathway is not expected to be regulated
in C. glutamicum. In the terpenoid production strains mentioned above genes have been integrated
and expressed from chromosomal locations using strong constitutive natural or synthetic promoters
rather than from IPTG inducible plasmids. This increased genetic stability as well as gene expression
represent a valuable strategy to further improve the patchoulol producing C. glutamicum strains
described here. Since a number of terpenes inhibit bacterial growth further strain engineering may be
guided, e.g., by RNAseq analysis of gene expression +/− patchoulol, to improve patchouli production
if patchoulol inhibits growth. This may also be relevant to adjust the fermentation process.
5. Conclusions
Metabolic engineering of C. glutamicum led, to the best of our knowledge, to the highest patchoulol
titers (up 60 mg L−1) and volumetric productivities (up 18 mg L−1 d−1) of microbial fermentation
reported to date. Production of patchoulol by recombinant C. glutamicum from substrates not competing
for use in human or animal nutrition such as the pentose sugars L-arabinose and D-xylose was
enabled. Patchoulol production from C. glutamicum was successfully demonstrated in batch and
fed-batch bioreactor set-ups with two-phase organic solvent overlay for capture of the semi-volatile
sesquiterpenoid product.
Supplementary Materials: The following are available online at http://www.mdpi.com/2073-4425/9/4/219/
s1, Figure S1: Phenotypes of patchoulol-overproducing PAT1 and PAT2 strains, Figure S2: GC-MS analysis
of patchoulol.
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